Pfizer Xeljanz's Long-term Dosing Raises Safety Concerns In Ulcerative Colitis
Executive Summary
US FDA's Gastrointestinal Drugs Advisory Committee will weigh proposed indication as agency appears uncertain whether higher dose can be used as long-term therapy.
You may also be interested in...
Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects
JAK inhibitor, now first oral UC medication in US, is approved for both 5mg and 10mg, but label currently discourages 10mg after 16 weeks.
Pfizer Xeljanz: Duration Of 10 mg Dose In Ulcerative Colitis Could Hinge On Post-Market Commitment
Postmarket trial looking at reduced doses in UC may be difficult to enroll, Pfizer argues; with approval of expanded indication seeming assured, another postmarket question for Xeljanz could look at impact of herpes zoster vaccine.
Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes
US FDA's Gastrointestinal Drugs Advisory Committee says higher dosing regimens can be used despite agency worries about safety with long-term use.